{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:07:50Z","timestamp":1793351270375,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.urolonc.2008.05.004","type":"journal-article","created":{"date-parts":[[2008,7,18]],"date-time":"2008-07-18T05:37:05Z","timestamp":1216359425000},"page":"496-501","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): A trial of the Eastern Cooperative Oncology Group"],"prefix":"10.1016","volume":"27","author":[{"given":"Jeffrey M.","family":"Ignatoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard Evan","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio M.","family":"Pow-Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M.","family":"Messing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Wilding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2008.05.004_bib1","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/ncpuro0784","article-title":"The management of superficial bladder cancer","volume":"4","author":"Dalbagni","year":"2007","journal-title":"Nat Clin Pract Urol"},{"key":"10.1016\/j.urolonc.2008.05.004_bib2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0022-5347(17)37317-2","article-title":"Management of local bacillus Calmette-Guerin failures in superficial bladder cancer","volume":"147","author":"Klein","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2008.05.004_bib3","first-page":"233A","article-title":"Intravesical AD 32 (N-trifluoroacetyladriamycin-14-valerate) in the treatment of patients with refractory bladder carcinoma\u2014clinical efficacy, pharmacology, and safety","volume":"153","author":"Greenberg","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2008.05.004_bib4","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0090-4295(96)00621-8","article-title":"Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder","volume":"49","author":"Greenberg","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2008.05.004_bib5","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0090-4295(00)00654-3","article-title":"Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer","volume":"56","author":"Patterson","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2008.05.004_bib6","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/S0022-5347(01)67427-5","article-title":"Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder","volume":"153","author":"Lamm","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2008.05.004_bib7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.urology.2004.04.026","article-title":"Current and new strategies in immunotherapy for superficial bladder cancer","volume":"64","author":"Perabo","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2008.05.004_bib8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0022-5347(17)46972-2","article-title":"Bacillus Calmette-Guerin immunotherapy for bladder cancer","volume":"134","author":"Lamm","year":"1985","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2008.05.004_bib9","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0022-5347(05)66410-5","article-title":"The fate of bacillus Calmette-Guerin after intravesical instillation","volume":"165","author":"Durek","year":"2001","journal-title":"J Urol"},{"issue":"Suppl 1","key":"10.1016\/j.urolonc.2008.05.004_bib10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000052381","article-title":"BCG intravesical instillations: Recommendations for side-effects management","volume":"37","author":"Rischmann","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2008.05.004_bib11","series-title":"Smith's General Urology","article-title":"Urothelial Cancers: Cancers of the renal pelvis, ureter, and bladder","author":"Carroll","year":"1992"},{"key":"10.1016\/j.urolonc.2008.05.004_bib12","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0022-5347(17)32741-6","article-title":"Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy","volume":"152","author":"Nadler","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2008.05.004_bib13","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S0022-5347(17)37452-9","article-title":"Bacillus Calmette-Guerin therapy for superficial bladder cancer: A 10-year follow-up","volume":"147","author":"Herr","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2008.05.004_bib14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0022-5347(17)38242-3","article-title":"Progression of Stage T1 bladder tumors after intravesical bacillus Calmette-Guerin","volume":"145","author":"Herr","year":"1991","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2008.05.004_bib15","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.juro.2006.11.090","article-title":"Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer","volume":"177","author":"Raj","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2008.05.004_bib16","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/ncpuro0784","article-title":"The management of superficial bladder cancer","volume":"4","author":"Dalbagni","year":"2007","journal-title":"Nat Clin Pract Urol"},{"key":"10.1016\/j.urolonc.2008.05.004_bib17","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1442-2042.2007.01696.x","article-title":"Intravesical instillation therapy with bacillus Calmette-Guerin for superficial bladder cancer: Study of the mechanism of bacillus Calmette-Guerin immunotherapy","volume":"14","author":"Shintani","year":"2007","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2008.05.004_bib18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1023\/A:1007199932271","article-title":"The best management of superficial bladder tumors: Comparing TUR alone vs. TUR combined with intravesical chemotherapy modalities?","volume":"32","author":"Altay","year":"2000","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.urolonc.2008.05.004_bib19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1067\/mcn.2001.117539","article-title":"Diagnosis and management of superficial bladder cancer","volume":"25","author":"Amling","year":"2001","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.urolonc.2008.05.004_bib20","first-page":"65","article-title":"Guidelines on diagnosis and treatment of superficial bladder cancer","volume":"56","author":"Oosterlinck","year":"2004","journal-title":"Minerva Urol Nefrol"},{"key":"10.1016\/j.urolonc.2008.05.004_bib21","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11864-002-0005-4","article-title":"Superficial bladder cancer","volume":"3","author":"Lamm","year":"2002","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.urolonc.2008.05.004_bib22","first-page":"1365","article-title":"N-trifluoroacetyladriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin","volume":"35","author":"Israel","year":"1975","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2008.05.004_bib23","unstructured":"Israel M, Khetarpal VK. Tissue distribution and metabolism of N-trifluoroacetyladriamycin-14-valerate (AD 32) compared with adriamycin in mice bearing established Lewis lung carcinomas tissue distribution and metabolism of N-trifluoroacetyladriamycin-14-valerate (AD 32) compared with adriamycin in mice bearing established Lewis lung carcinomas. Proceedings of the 13th International Congress of Chemotherapy, Vienna, Austria, Aug 28\u2013Sept 2, 1983 [Abstract]."},{"key":"10.1016\/j.urolonc.2008.05.004_bib24","series-title":"Recent Results in Cancer Research","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-81565-2_2","article-title":"Preclinical Rationale and Phase I Clinical Trials of the Adriamycin Analog AD 32","author":"Blum","year":"1981"},{"key":"10.1016\/j.urolonc.2008.05.004_bib25","first-page":"233a","article-title":"Intravesical AD 32 (N-trifluoroacetyladriamycin-14-valerate) in the treatment of patients with refractory bladder carcinoma\u2014clinical efficacy, pharmacology, and safety","volume":"153","author":"Greenberg","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2008.05.004_bib26","first-page":"919","article-title":"Initial clinical evaluation of N-trifluoroacetyladriamycin-14-valerate (AD-32), an adriamycin analog","volume":"63","author":"Blum","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.urolonc.2008.05.004_bib27","series-title":"Anthracycline Antibiotics in Cancer Therapy","article-title":"Phase II Evaluation of Ntrifluoroacetyladriamycin-14-valerate (AD 32)","author":"Garnick","year":"1982"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143908001166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143908001166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:56:06Z","timestamp":1761040566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143908001166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S1078143908001166"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2008.05.004","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): A trial of the Eastern Cooperative Oncology Group","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2008.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}